Raymond James Financial Services Advisors, Inc. Beam Therapeutics Inc. Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 9,485 shares of BEAM stock, worth $271,365. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,485
Previous 9,158
3.57%
Holding current value
$271,365
Previous $214,000
8.41%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding BEAM
# of Institutions
245Shares Held
76.7MCall Options Held
458KPut Options Held
202K-
Farallon Capital Management LLC San Francisco, CA8.21MShares$235 Million1.01% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$218 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.62MShares$218 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.07MShares$202 Million1.53% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.83MShares$138 Million71.21% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $2.01B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...